180 related articles for article (PubMed ID: 31502695)
41. Pediatric pharmacogenomics: challenges and opportunities: on behalf of the Sanford Children's Genomic Medicine Consortium.
Gregornik D; Salyakina D; Brown M; Roiko S; Ramos K
Pharmacogenomics J; 2021 Feb; 21(1):8-19. PubMed ID: 32843689
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of Current Regulation and Guidelines of Pharmacogenomic Drug Labels: Opportunities for Improvements.
Shekhani R; Steinacher L; Swen JJ; Ingelman-Sundberg M
Clin Pharmacol Ther; 2020 May; 107(5):1240-1255. PubMed ID: 31715018
[TBL] [Abstract][Full Text] [Related]
43. Design and evaluation of a pharmacogenomics information resource for pharmacists.
Romagnoli KM; Boyce RD; Empey PE; Ning Y; Adams S; Hochheiser H
J Am Med Inform Assoc; 2017 Jul; 24(4):822-831. PubMed ID: 28339805
[TBL] [Abstract][Full Text] [Related]
44. Pediatric pharmacology: the path clears for a noble mission.
Wilson JT
J Clin Pharmacol; 1993 Mar; 33(3):210-2. PubMed ID: 8463433
[TBL] [Abstract][Full Text] [Related]
45. Food-Drug Effects and Pediatric Drug Development Studies Submitted to the US Food and Drug Administration, 2012-2022.
Tunehag KR; George B; Samuels S; Vo K; Arya V; Abulwerdi G; Burckart GJ
J Clin Pharmacol; 2024 Jun; 64(6):697-703. PubMed ID: 38294346
[TBL] [Abstract][Full Text] [Related]
46. Paediatric labelling requirements. Implications for pharmacokinetic studies.
Wilson JT; Kearns GL; Murphy D; Yaffe SJ
Clin Pharmacokinet; 1994 Apr; 26(4):308-25. PubMed ID: 8013163
[TBL] [Abstract][Full Text] [Related]
47. Pharmacogenomics in the assessment of therapeutic risks versus benefits: inside the United States Food and Drug Administration.
Zineh I; Pacanowski MA
Pharmacotherapy; 2011 Aug; 31(8):729-35. PubMed ID: 21923598
[TBL] [Abstract][Full Text] [Related]
48. Predictive Pediatric Modeling and Simulation Using Ontogeny Information.
Ince I; Solodenko J; Frechen S; Dallmann A; Niederalt C; Schlender J; Burghaus R; Lippert J; Willmann S
J Clin Pharmacol; 2019 Sep; 59 Suppl 1():S95-S103. PubMed ID: 31502689
[TBL] [Abstract][Full Text] [Related]
49. Obesity and Pediatric Drug Development.
Vaughns JD; Conklin LS; Long Y; Zheng P; Faruque F; Green DJ; van den Anker JN; Burckart GJ
J Clin Pharmacol; 2018 May; 58(5):650-661. PubMed ID: 29350758
[TBL] [Abstract][Full Text] [Related]
50. Integration of pharmacogenetics and pharmacogenomics in drug development: implications for regulatory and medical decision making in pediatric diseases.
Piana C; Surh L; Furst-Recktenwald S; Iolascon A; Jacqz-Aigrain EM; Jonker I; Russo R; van Schaik RH; Wessels J; Della Pasqua OE
J Clin Pharmacol; 2012 May; 52(5):704-16. PubMed ID: 21566202
[TBL] [Abstract][Full Text] [Related]
51. Personalized medicine and rescuing "unsafe" drugs with pharmacogenomics: a regulatory perspective.
Avery M
Food Drug Law J; 2010; 65(1):37-65, i-ii. PubMed ID: 24475534
[TBL] [Abstract][Full Text] [Related]
52. New pediatric dosage rules: information and testing.
Feeg VD
Pediatr Nurs; 1998; 24(6):518, 613. PubMed ID: 10085992
[No Abstract] [Full Text] [Related]
53. Personalized medicine: Genetic risk prediction of drug response.
Zhang G; Nebert DW
Pharmacol Ther; 2017 Jul; 175():75-90. PubMed ID: 28213088
[TBL] [Abstract][Full Text] [Related]
54. PhRMA white paper on ADME pharmacogenomics.
Williams JA; Andersson T; Andersson TB; Blanchard R; Behm MO; Cohen N; Edeki T; Franc M; Hillgren KM; Johnson KJ; Katz DA; Milton MN; Murray BP; Polli JW; Ricci D; Shipley LA; Vangala S; Wrighton SA
J Clin Pharmacol; 2008 Jul; 48(7):849-89. PubMed ID: 18524998
[TBL] [Abstract][Full Text] [Related]
55. A retrospective analysis of actionable pharmacogenetic/genomic biomarker language in FDA labels.
Yamazaki S
Clin Transl Sci; 2021 Jul; 14(4):1412-1422. PubMed ID: 33742770
[TBL] [Abstract][Full Text] [Related]
56. FDA labeling status of pediatric medications.
Yoon EY; Davis MM; El-Essawi H; Cabana MD
Clin Pediatr (Phila); 2006; 45(1):75-7. PubMed ID: 16429220
[No Abstract] [Full Text] [Related]
57. Role of Quantitative Clinical Pharmacology in Pediatric Approval and Labeling.
Mehrotra N; Bhattaram A; Earp JC; Florian J; Krudys K; Lee JE; Lee JY; Liu J; Mulugeta Y; Yu J; Zhao P; Sinha V
Drug Metab Dispos; 2016 Jul; 44(7):924-33. PubMed ID: 27079249
[TBL] [Abstract][Full Text] [Related]
58. Progress in Drug Development-Pediatric Dose Selection: Workshop Summary.
Wang J; van den Anker JN; Burckart GJ
J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S13-S21. PubMed ID: 34185909
[TBL] [Abstract][Full Text] [Related]
59. Is pediatric labeling really necessary?
Christensen ML; Helms RA; Chesney RW
Pediatrics; 1999 Sep; 104(3 Pt 2):593-7. PubMed ID: 10469796
[No Abstract] [Full Text] [Related]
60. Review of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act: What can the obstetric community learn from the pediatric experience?
Ren Z; Zajicek A
Semin Perinatol; 2015 Nov; 39(7):530-1. PubMed ID: 26455383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
